Zydus Lifesciences share price rose in the opening trade on November 28 following the company received tentative approval for Empagliflozin and Linagliptin tablets.
At 09:16am, Zydus Lifesciences was quoting at Rs 944.40, up Rs 7.15, or 0.76 percent, on the BSE.
".... has received tentative approval from the United States Food and Drug Administration (USFDA) for Empagliflozin and Linagliptin tablets, 10 mg/5 mg and 25 mg/5 mg.
Empagliflozin and Linagliptin tablets in a combination are indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when
treatment with both empagliflozin and linagliptin is appropriate.
The tablets will be produced at the group’s formulation manufacturing facility at SEZ, Ahmedabad.
Since FY 2003-04, the company had received 428 approvals and filed 487 ANDAs.
Catch all the market action on our live blog
Earlier in this week, the company entered into an exclusive licensing and commercialization agreement with RK Pharma Inc of the US for a novel sterile injectable 505(b)(2) oncology supportive care product for the US market.
Under the terms of this agreement, RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA submission and commercialization of the product in the US.
Also, received final approval from the USFDA for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg.
In the previous trading session, the share closed at Rs 937.25, down Rs 3.20, or 0.34 percent.
The share touched a 52-week high of Rs 1,059.00 and a 52-week low of Rs 797.05 on 19 September, 2025 and 07 April, 2025, respectively.
Currently, the stock is trading 11.5 percent below its 52-week high and 17.59 percent above its 52-week low.
The market capitalisation of the company stands at Rs 94,309.28 crore.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
